09 June, 2020 The specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications announced the successful closure of a £1.5 million (US$1.9 million) series A investment round to accelerate the global scale-up of its commercial operations. According to Cambridge based Qkine, the funding… Read More
Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More
15 May, 2020 The Swiss next-generation bioanalytical instruments specialist announced a collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterise immunological responses to SARS-CoV-2 such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the coronavirus. The collaboration aims… Read More
By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for high quality… Read More
By Andrii Lozoniuk Volume 21 Issue 2 - Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise… Read More
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an… Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More
Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More
Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These vesicles can… Read More
Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and… Read More
Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency By Dr Philip S. Jones and Dr Stuart P. McElroy While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening campaign, in our… Read More
Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the… Read More
Fail Early, Fail Fast - A phenotypic rescue approach By Dr Anne-Marie Zuurmond, et al. New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery programme is often lacking. In pharmacological or genetic perturbation studies using complex biological assays,… Read More
Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More
Application of bioinformatics in support of precision medicine By Mike Furness and John Wise Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. With the support of new technologies and tools, bioinformatics can play an important… Read More
The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries… Read More